Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 Sep;78(5):495-502.
doi: 10.1038/ki.2010.150. Epub 2010 May 26.
Collaborators, Affiliations
- PMID: 20505654
- DOI: 10.1038/ki.2010.150
Free article
Randomized Controlled Trial
Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura
Evangéline Pillebout et al. Kidney Int. 2010 Sep.
Free article
Abstract
Henoch Schönlein Purpura (HSP) is a common disease in children, usually associated with a good prognosis. In adults there are no prospective studies concerning its prognosis or treatment, especially in cases of severe visceral involvement. Here we compared steroid therapy without or with cyclophosphamide co-treatment in adults with severe HSP in a 12-month, multi-center, prospective, open-label trial that treated 54 adults with biopsy-proven HSP including proliferative glomerulonephritis and severe visceral manifestations. All received steroids; however, 25 were randomized to also receive cyclophosphamide. The primary endpoint that occurred in three patients in each group was complete disease remission defined as zero on the Birmingham Vasculitis Activity Score with no persistent or new clinical and/or biological vasculitis at 6 months. No patient had active visceral involvement. The secondary endpoints were renal outcome, deaths, and adverse events at 12 months. Renal function, proteinuria, safety data, incidence of diabetes, and severe infections were similar between the two groups. At the last follow-up, renal function remained stable. The small population size of our study does not permit definitive conclusions; however, we suggest that treatment of adults with severe HSP by adding cyclophosphamide provides no benefit compared with steroids alone.
Trial registration: ClinicalTrials.gov NCT00190229.
Comment in
- Could no benefit of cyclophosphamide treatment be due to decreased fibrinolytic activity in adults with severe Henoch Schönlein nephritis?
Shin JI, Park SJ, Kim JH. Shin JI, et al. Kidney Int. 2011 Apr;79(8):922. doi: 10.1038/ki.2011.5. Kidney Int. 2011. PMID: 21451539 No abstract available.
Similar articles
- Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide.
Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Flynn JT, et al. Am J Nephrol. 2001 Mar-Apr;21(2):128-33. doi: 10.1159/000046235. Am J Nephrol. 2001. PMID: 11359020 Clinical Trial. - [Multicenter investigation of diagnosis and treatment of Henoch-Schonlein purpura nephritis in childhood].
Working Group for National Survey on Status of Diagnosis and Treatment of Childhood Renal Disease. Working Group for National Survey on Status of Diagnosis and Treatment of Childhood Renal Disease. Zhonghua Er Ke Za Zhi. 2013 Dec;51(12):881-7. Zhonghua Er Ke Za Zhi. 2013. PMID: 24495756 Chinese. - Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schönlein purpura in adults: a case series.
Augusto JF, Sayegh J, Delapierre L, Croue A, Tollis F, Cousin M, Subra JF. Augusto JF, et al. Am J Kidney Dis. 2012 May;59(5):663-9. doi: 10.1053/j.ajkd.2011.12.015. Epub 2012 Jan 31. Am J Kidney Dis. 2012. PMID: 22300649 Clinical Trial. - Pulmonary haemorrhage in a 6-year-old boy with Henoch-Schönlein purpura.
Besbas N, Duzova A, Topaloglu R, Gok F, Ozaltin F, Ozen S, Bakkaloglu A. Besbas N, et al. Clin Rheumatol. 2001;20(4):293-6. doi: 10.1007/pl00011205. Clin Rheumatol. 2001. PMID: 11529643 Review. - Therapy for children with henoch-schonlein purpura nephritis: a systematic review.
Zaffanello M, Brugnara M, Franchini M. Zaffanello M, et al. ScientificWorldJournal. 2007 Jan 10;7:20-30. doi: 10.1100/tsw.2007.23. ScientificWorldJournal. 2007. PMID: 17221139 Free PMC article. Review.
Cited by
- Steroid-Dependent Recurrent IgA Vasculitis in a 19-Year-Old Woman.
Berrett H, Gohil S, Kurian R, Neyman P. Berrett H, et al. HCA Healthc J Med. 2024 Aug 1;5(4):453-458. doi: 10.36518/2689-0216.1660. eCollection 2024. HCA Healthc J Med. 2024. PMID: 39290479 Free PMC article. - Navigating Adult-Onset IgA Vasculitis-Associated Nephritis.
Gan MY, Chua FZY, Chang ZY, Chua YT, Chan GC. Gan MY, et al. Life (Basel). 2024 Jul 25;14(8):930. doi: 10.3390/life14080930. Life (Basel). 2024. PMID: 39202674 Free PMC article. Review. - Successful rituximab therapy in adult-onset IgA vasculitis with diffuse alveolar hemorrhage and renal failure: a case report.
Ghebranious M, Leslie M, Manthuruthil C, Dhamankar O, Kazi S. Ghebranious M, et al. AME Case Rep. 2023 Nov 21;8:12. doi: 10.21037/acr-23-43. eCollection 2024. AME Case Rep. 2023. PMID: 38234356 Free PMC article. - Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement.
Przygocka A, Berti GM, Campus A, Tondolo F, Vischini G, Fabbrizio B, La Manna G, Baraldi O. Przygocka A, et al. BMC Nephrol. 2023 Dec 20;24(1):381. doi: 10.1186/s12882-023-03439-0. BMC Nephrol. 2023. PMID: 38124070 Free PMC article. - IgA vasculitis in adults, pediatrics and non-vasculitic IgA nephropathy, retrospective analysis from 2 centers.
Levanon S, Gotloib V, Kraus Y, Novofastovski I, Brikman S, Fawaz A, Egbaria M, Butbul Aviel Y, Balbir-Gurman A, Mader R, Bieber A. Levanon S, et al. Medicine (Baltimore). 2023 Dec 15;102(50):e36521. doi: 10.1097/MD.0000000000036521. Medicine (Baltimore). 2023. PMID: 38115301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical